Chronic Lymphocytic Leukemia Treatment Companies

ID: MRFR/Pharma/5435-HCR

90 Pages

Rahul Gotadki

Last Updated: February 16, 2025

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Treatment for CLL may involve various approaches, including chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Companies involved in CLL treatment play crucial roles in developing and providing medications, therapies, and diagnostic tools to manage the disease.

Chronic Lymphocytic Leukemia Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.31%

2024 Market Size$ 5.75 Billion

2025 Market Size$ 6.06 Billion

2035 Market Size$ 10.16 Billion

Key Players

AbbVie

Roche

Gilead Sciences

Johnson & Johnson

Novartis

Bristol-Myers Squibb

Trends

Rise of Targeted Therapies
Growth of Immunotherapy
Emphasis on Combination Therapies

Opportunities

Advancements in Precision Medicine
Rising Investment in Oncology Research
Growing Awareness and Education Initiatives

Summary Table of Contents Segmentation Methodology Download PDF

Customize Report

Certified Researchers

Top Industry Leaders in the Chronic Lymphocytic Leukemia Treatment Market

Chronic Lymphocytic Leukemia Treatment Key Companies

Latest Chronic Lymphocytic Leukemia Treatment Companies Update

Pirtobrutinib (Rozlytrek®): In December 2023, the FDA granted accelerated approval to pirtobrutinib for adults with CLL or small lymphocytic lymphoma (SLL) who previously received at least two lines of prior therapy, including a BTK inhibitor and a BCL2 inhibitor. This signifies the first non-covalent BTK inhibitor approved for CLL and represents a significant milestone for targeted therapy options.

Venetoclax (Venclexta®): In October 2023, the FDA approved venetoclax in combination with obinutuzumab for the frontline treatment of patients with CLL and a specific genetic mutation (17p deletion). This expands the use of venetoclax beyond relapsed/refractory CLL and offers a highly effective option for newly diagnosed patients.

Zanubrutinib (Brukinsa®): Positive results from the Phase 3 ELEVATE-RR trial evaluating zanubrutinib in combination with venetoclax for previously untreated CLL were presented at ASCO 2023. This combination demonstrated superior progression-free survival and minimal residual disease compared to standard chemoimmunotherapy.

List of Chronic Lymphocytic Leukemia Treatment Key Companies in the Market

Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Genmab A/S
Teva Pharmaceutical Industries Ltd
Genentech Inc
Genzyme Corporation
AbbVie Inc
Gilead
Novartis AG
Johnson & Johnson Services Inc
AstraZeneca
TG Therapeutics Inc
Ziopharm Oncology Inc

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”